Pharmacogenetics implementation in the clinics: information and guidelines for germline variants

Abstract

The aim of this work was to supply an overview of the germline Pharmacogenetics that can be already implemented in the oncology clinical practice. An explanation of the three pillars considered necessary for determining which genetic polymorphisms should be used has been provided. These are PharmGKB single nucleotide polymorphism (SNP)-Drug Clinical Annotations with levels of evidence 1 or 2; the genetic information provided in the drug labels by the drug regulatory main agencies (Food and Drug Administration and European Medicines Agency, mainly); and the guidelines elaborated by international expert consortia (mainly Clinical Pharmacogenetics Implementation Consortium and Dutch Pharmacogenetics Working Group). A summary of the relevant SNPs and the recommendations on how to apply their results has also been compiled.

Keywords

Polymorphisms / Pharmacogenetic / PharmGKB / guidelines / oncology / clinical implementation

References

[1] Ross CJD,Rod Rassekh S,Shereck E.Pharmacogenomics of serious adverse drug reactions in pediatric oncology..J Popul Ther Clin Pharmacol2011;18:134-51

[2] Conyers R,Elliott D.Systematic review of pharmacogenomics and adverse drug reactions in paediatric oncology patients..Pediatr Blood Cancer2018;65:e26937

[3] Whirl-Carrillo M,Hebert JM,Sangkuhl K.Pharmacogenomics knowledge for personalized medicine..Clin Pharmacol Ther2012;92:414-7 PMCID:PMC3660037

[4] Rodríguez AE,Bernal ML,Peiró AM.Personalized medicine into health national services: barriers and potentialities..Drug Metab Pers Ther2018;

[5] Caudle KE,Freimuth RR,Burlison JD.Standardizing terms for clinical pharmacogenetic test results: consensus terms from the clinical pharmacogenetics implementation consortium (CPIC)..Genet Med2017;19:215-23 PMCID:PMC5253119

[6] Swen JJ,de Boer A,Maitland-Van Der Zee AH.Pharmacogenetics: from Bench to Byte - an update of guidelines..Clin Pharmacol Ther2011;89:662-73

[7] García-González X,Herrero MJ,López-Fernández LA.Clinical implementation of pharmacogenetics..Drug Metab Pers Ther2016;31:9-16

[8] U S Food and Drug Administration. Available from: https://www.fda.gov/. [Last accessed on 18 Feb 2019]

[9] European Medicines Agency. Available from: https://www.ema.europa.eu/en. [Last accessed on 18 Feb 2019]

[10] Pharmaceuticals and Medical Devices Agency. Available from: http://www.pmda.go.jp/english/. [Last accessed on 18 Feb 2019]

[11] Drugs and Health Products - Canada.ca. Available from: https://www.canada.ca/en/health-canada/services/drugs-health-products.html. [Last accessed on 18 Feb 2019]

[12] Relling MV.CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network..Clin Pharmacol Ther2011;89:464-7 PMCID:PMC3098762

[13] Swen JJ,de Goede AL,Mulder H.Pharmacogenetics: from Bench to Byte..Clin Pharmacol Ther2008;83:781-7

[14] Bank PCD,Swen JJ,Whirl-Carrillo M.A comparison of the guidelines of the Clinical Pharmacogenetics Implementation Consortium and the Dutch Pharmacogenetics Working Groups..Clin Pharmacol Ther2018;103:599-618 PMCID:PMC5723247

[15] Lee JW,Rassekh SR,Hwang S.Clinical practice recommendations for the management and prevention of cisplatin-induced hearing loss using Pharmacogenetic markers..Ther Drug Monit2016;38:423-31

[16] Gaedigk A,Whirl-Carrillo M,Steven Leeder J.Prediction of CYP2D6 phenotype from genotype across world populations..Genet Med2017;19:69-76 PMCID:PMC5292679

[17] Relling MV,Sandborn WJ,Pui CH.Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing..Clin Pharmacol Ther2011;89:387-91 PMCID:PMC3098761

[18] Relling MV,Sandborn WJ,Pui CH.Clinical pharmacogentics implementation consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing: 2013 Update..Clin Pharmacol Ther2013;93:324-5 PMCID:PMC3604643

[19] Relling MV,Whirl-Carrillo M,Pui CH.Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 update..Clin Pharmacol Ther2018;

[20] Amstutz U,Offer SM,Schellens JHM.Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update..Clin Pharmacol Ther2018;103:210-6 PMCID:PMC5760397

[21] Bell GC,Whirl-Carrillo M,Hikino K.Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 genotype and use of ondansetron and tropisetron..Clin Pharmacol Ther2017;102:213-8 PMCID:PMC5479760

[22] Goetz MP,Guchelaar HJ,Province M.Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 and Tamoxifen therapy..Clin Phramacol Ther2018;103:770-7 PMCID:PMC5931215

[23] Alsous M,Abdel Jalil M,Yacoub S.Genetic Polymorphism of Thiopurine S-methyltransferase in Children with Acute Lymphoblastic Leukemia in Jordan..Asian Pac J Cancer Prev2018;19:199-205 PMCID:PMC5844618

[24] Bradford K.Optimizing 6-mercaptopurine and azathioprine therapy in the management of inflammatory bowel disease..World J Gastroenterol2011;17:4166-73 PMCID:PMC3208360

[25] Moriyama T,Perez-Andreu V,Klussmann FA.NUDT15 polymorphisms alter thiopurine metabolism and hematopoietic toxicity..Nat Genet2016;48:367-73 PMCID:PMC5029084

[26] Yang SK,Baek J,Zhao W.A common missense variant in NUDT15 confers susceptibility to thiopurine-induced leukopenia..Nat Genet2014;46:1017-20 PMCID:PMC4999337

[27] Chiengthong K,Muensri S,Sosothikul D.NUDT15 c.415C>T increases risk of 6-mercaptopurine induced myelosuppression during maintenance therapy in children with acute lymphoblastic leukemia..Haematologica2016;101:e24-6 PMCID:PMC4697903

[28] Meulendijks D,Sonke GS,Froehlich TK.Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data..Lancet Oncol2015;16:1639-50

[29] van Kuilenburg AB.Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil..Eur J Cancer2004;40:939-50

[30] Liu X,Kuang Q,Xu W.Association between UGT1A1*28 polymorphisms and clinical outcomes of irinotecan-based chemotherapies in colorectal cancer: a meta-analysis in Caucasians..PLoS One2013;8:e58489 PMCID:PMC3597733

[31] Brandi G,Raibaud P,Bridonneau C.Intestinal microflora and digestive toxicity of irinotecan in mice..Clin Cancer Res2006;12:1299-307

[32] Lévesque E,Harvey M,Jonker D.Refining the UGT1A haplotype associated with irinotecan-induced hematological toxicity in metastatic colorectal cancer patients treated with 5-fluorouracil/irinotecan-based regimens..J Pharmacol Exp Ther2013;345:95-101 PMCID:PMC3920089

[33] Gammal RS,Haidar CE,Gaur AH.Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for UGT1A1 and Atazanavir Prescribing..Clin Pharmacol Ther2016;99:363-9 PMCID:PMC4785051

[34] Etienne-Grimaldi MC,Thomas F,Picard N.UGT1A1 genotype and irinotecan therapy: general review and implementation in routine practice..Fundam Clin Pharmacol2015;29:219-37

[35] Kovac AL.Comparative Pharmacology and guide to the use of the serotonin 5-HT3 receptor antagonists for postoperative nausea and vomiting..Drugs2016;76:1719-35

[36] Sanwald P,Dow J.Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of dolasetron. Comparison with other indole-containing 5-HT3 antagonists..Drug Metab Dispos1996;24:602-9

[37] Bloomer JC,Smith GJ,Clarke SE.Characterisation of the cytochrome P450 enzymes involved in the in vitro metabolism of granisetron..Br J Clin Pharmacol1994;38:557-66 PMCID:PMC1364919

[38] Gaedigk A,Pearce R,Kennedy MJ.The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype..Clin Pharmacol Ther2008;83:234-42

[39] Sanchez Spitman AB,Gelderblom H,Swen JJ.Effect of CYP3A4*22, CYP3A5*3, and CYP3A combined genotypes on tamoxifen metabolism..Eur J Clin Pharmacol2017;73:1589-98 PMCID:PMC5684327

[40] Desta Z,Soukhova NV.Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6..J Pharmacol Exp Ther2004;310:1062-75

[41] Thota K,Basaveswara RMV.Detection of cytochrome P450 polymorphisms in breastcancer patients may impact on tamoxifen therapy..Asian Pac J Cancer Prev2018;19:343-50 PMCID:PMC5980918

[42] Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials..Lancet2015;386:1341-52

[43] Maor R,Wanous AA,Pruthi S.Attenuated peripheral endothelial function among women treated with aromatase inhibitors for breast cancer..Coron Artery Dis2018;29:687-93

[44] Hertz DL,Ibrahim JG,Weck KE.Tamoxifen dose escalation in patients with diminished CYP2D6 activity normalizes endoxifen concentrations without increasing toxicity..Oncologist2016;21:795-803 PMCID:PMC4943390

[45] Ho GY,Coward JIG.Cisplatin versus carboplatin: comparative review of therapeutic management in solid malignancies..Crit Rev Oncol Hematol2016;102:37-46

[46] Lui G,Denoyelle F,Brugières L.Association between genetic polymorphisms and platinum-induced ototoxicity in children..Oncotarget2018;9:30883-93 PMCID:PMC6089394

[47] Langer T,Radtke S,Zolk O.Understanding platinum-induced ototoxicity..Trends Pharmacol Sci2013;34:458-69

[48] Liberman PHP,Schultz C,de Paula CAA.Contribution of the GSTP1 c.313A>G variant to hearing loss risk in patients exposed to platin chemotherapy during childhood..Clin Transl Oncol2018;

[49] Brown AL,Okcu MF,Rednam S.SOD2 genetic variant associated with treatment-related ototoxicity in cisplatin-treated pediatric medulloblastoma..Cancer Med2015;4:1679-86 PMCID:PMC4673994

[50] Lopes-Aguiar L,Nogueira GAS,Visacri MB.XPD c.934G>A polymorphism of nucleotide excision repair pathway in outcome of head and neck squamous cell carcinoma patients treated with cisplatin chemoradiation..Oncotarget2017;8:16190-201 PMCID:PMC5369956

[51] Drögemöller BI,Bhavsar AP,Brooks B.Association between SLC16A5 genetic variation and cisplatin-induced ototoxic effects in adult patients with testicular cancer..JAMA Oncol2017;3:1558-62 PMCID:PMC5824214

[52] Lanvers-Kaminsky C,Malath I,Eveslage M.Human OCT2 variant c.808G>T confers protection effect against cisplatin-induced ototoxicity..Pharmacogenomics2015;16:323-32 PMCID:PMC4865798

[53] Ross CJD,Dubé MP,Rassekh SR.Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy..Nat Genet2009;41:1345-9

[54] Pussegoda K,Visscher H,Brooks B.Replication of TPMT and ABCC3 genetic variants highly associated with cisplatin-induced hearing loss in children..Clin Pharmacol Ther2013;94:243-51 PMCID:PMC4006820

[55] Yang JJ,Huang J,Wu J.The role of inherited TPMT and COMT genetic variation in cisplatin-induced ototoxicity in children with cancer..Clin Pharmacol Ther2013;94:252-9 PMCID:PMC3883563

[56] Thiesen S,Jorgensen AL,Manzo V.TPMT, COMT and ACYP2 genetic variants in paediatric cancer patients with cisplatin-induced ototoxicity..Pharmacogenet Genomics2017;27:213-22 PMCID:PMC5432027

[57] Oliveira E,Alves S,Prata MJ.Do the distribution patterns of polymorphisms at the thiopurine S-methyltransferase locus in sub-Saharan populations need revision? Hints from Cabinda and Mozambique..Eur J Clin Pharmacol2007;63:703-6

[58] Hagleitner MM,Patino-Garcia A,Gonzalez-Neira A.Influence of genetic variants in TPMT and COMT associated with cisplatin induced hearing loss in patients with cancer: two new cohorts and a meta-analysis reveal significant heterogeneity between cohorts..PLoS One2014;9:e115869 PMCID:PMC4281251

[59] Krynetski E.Drug methylation in cancer therapy: lessons from the TPMT polymorphism..Oncogene2003;22:7403-13

[60] Stern JW.Prospective study of carboplatin-based chemotherapy for pediatric germ cell tumors..Med Pediatr Oncol2002;39:163-7

[61] Shaikh F,Hale J,Frazier L.Is there a role for carboplatin in the treatment of malignant germ cell tumors? A systematic review of adult and pediatric trials..Pediatr Blood Cancer2013;60:587-92

[62] Kolinsky DC,Karzon R,Hayashi RJ.Late onset hearing loss: a significant complication of cancer survivors treated with cisplatin containing chemotherapy regimens..J Pediatr Hematol Oncol2010;32:119-23

[63] Grewal S,Reymond R,Hodge C.Auditory late effects of childhood cancer therapy: a report from the Children’s Oncology Group..Pediatrics2010;125:e938-50 PMCID:PMC3106205

[64] Ellison LF,Mery LS.Childhood and adolescent cancer survival: a period analysis of data from the Canadian Cancer Registry..Eur J Cancer2007;43:1967-75

[65] Scully RE.Anthracycline cardiotoxicity in long-term survivors of childhood cancer..Cardiovascular Toxicology2007;7:122-8

[66] Minotti G.Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity..Pharmacol Rev2004;56:185-229

[67] Cortés-Funes H.Role of anthracyclines in the era of targeted therapy..Cardiovasc Toxicol2007;7:56-60

[68] Aminkeng F,Visscher H,Li Y.A coding variant in RARG confers susceptibility to anthracycline-induced cardiotoxicity in childhood cancer..Nat Genet2015;47:1079-84 PMCID:PMC4552570

[69] Aminkeng F,Rassekh SR,Rieder MJ.Recommendations for genetic testing to reduce the incidence of anthracycline-induced cardiotoxicity..Br J Clin Pharmacol2016;82:683-95 PMCID:PMC5338111

[70] Visscher H,Rassekh SR,Caron HN.Validation of variants in SLC28A3 and UGT1A6 as genetic markers predictive of anthracycline-induced cardiotoxicity in children..Pediatr Blood Cancer2013;60:1375-81

[71] Ryerson AB,Wasilewski-Masker K,Meacham L.Assessing anthracycline-treated childhood cancer survivors with advanced stress echocardiography..Pediatr Blood Cancer2015;62:502-8

[72] Tuzovic M,Kianmahd S.Natural history of myocardial deformation in children, adolescents, and young adults exposed to anthracyclines: systematic review and meta-analysis..Echocardiography2018;35:922-34

[73] Rose-Felker K,Hong BJ.Cardio-oncology related to heart failure: pediatric considerations for cardiac dysfunction..Heart Failure Clinics2017;13:311-25

[74] Kaudle KE,Klein TE,Pratt VM.Standardization can accelerate the adoption of pharmacogenomics: current status and the path forward..Pharmacogenomics2018;19:847-60 PMCID:PMC6123879